Prophylactic interventions for oral toxicities with the GPRC5D×CD3 bispecific antibody talquetamab in relapsed/refractory multiple myeloma: An update on the open-label, phase 2, randomized TALISMAN study.

Authors: Rakesh Popat, Alexa Laheij, Niels W.C.J. van de Donk, Richard L. Doty, Jim Omel, Brea Lipe, Leo Rasche, Ajai Chari, Kelly Kato, Shaozhou Ken Tian, Deeksha Vishwamitra, Jacqueline Speier, Jennifer Schultz, Kasey Bolyard, Kathleen Gray, Gloria Aguilar, Mariana Fernandez, Keqin Qi, Larysa Jessica Sanchez

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps7565

Source: Full article

---

Abstract

TPS7565